narlaprevir: Clinical Trials

7 completed, 1 terminated. 4 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	4	Completed 3, Terminated 1
Phase 1	3	Completed 3
Phase 3	2	Completed 1, Terminated 1

Follow narlaprevir: new trials by email Literature Review of narlaprevir trials Research Report on narlaprevir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Narlaprevir, Ritonavir, Sofosbuvir - Chronic Hepatitis c Genotype 1	Phase 2	Completed	R-Pharm	85	2019-05-06	2022-10-31
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b Narlaprevir, Ritonavir, Daclatasvir - Chronic Hepatitis C Genotype 1b	Phase 2	Completed	R-Pharm	105	2017-11-27	2018-12-19
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate - Healthy	Phase 1	Completed	R-Pharm	36	2017-04-24	2019-02-19
Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study) Narlaprevir, Ritonavir, Placebo Narlaprevir - Hepatitis C	Phase 3	Completed	R-Pharm	420	2014-05-07	2019-02-07
A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers Narlaprevir, Ritonavir - Hepatic Impairment	Phase 1	Completed	R-Pharm	32	2013-11-08	2019-05-22
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) peginterferon alfa 2b, ribavirin, SCH 900518 - Hepatitis C, Chronic	Phase 2	Completed	Merck Sharp & Dohme LLC	111	2008-11-01	2015-01-22
Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695) Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron), Drug: SCH 900518 Biologic: Peginterferon alfa-2b, Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron) - Hepatitis C, Chronic	Phase 1	Completed	Merck Sharp & Dohme LLC	41	2007-07-01	2015-02-09
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Boceprevir, Narlaprevir, Peginterferon alfa-2b - Hepatitis C, Chronic, Hepacivirus	Phase 2 / Phase 3	Terminated	Merck Sharp & Dohme LLC	1954	2007-02-20	2018-09-11

Conditions studied

Hepatitis C (3)  ·  Hepatitis C, Chronic (3)  ·  Bronchiolitis Obliterans Syndrome (2)  ·  Coinfection (1)  ·  Hepatitis (1)

Sponsors

R-Pharm (5)  ·  Merck Sharp & Dohme LLC (3)

Countries

Russia (5)  ·  Georgia (1)

Top investigators

Mikhail Samsonov (5)

Results publications

PMID 20938912, PMID 23490393, PMID 27219495, PMID 27645244